文献速递治疗药物监测与药物基因组学特殊人群用药

辛辛那提儿童医院CYP2D6指导阿片类药物处方的实施经验

Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.
PubMed 文献 · Am J Health Syst Pharm · 2023-01-01

本文描述了在一家四级护理非营利性儿科学术医疗中心实施以CYP2D6为重点的药物遗传学检测以指导阿片类药物处方的过程。2004年起该中心实施CYP2D6代谢表型检测以指导可待因处方,检测与报告随检测平台、基因型到表型解读、电子健康记录及FDA指南变化而更新。检测使用量随研究项目需求增加而上升,随FDA对可待因的警告导致羟考酮处方增加而下降;对处方者及患者家庭的教育和电子健康记录功能提高了基因型指导术后羟考酮处方的依从性。

要点

  • CYP2D6药物遗传学检测可指导儿科阿片类药物个体化处方。
  • 检测与报告需随证据、指南及FDA警告持续更新。
  • 处方者教育结合电子健康记录功能可提高基因型指导处方的依从性。

核心结论

  • 儿童阿片类药物处方的药物遗传学检测实施随累积证据和指南演变,需要改变结果报告和推荐。

研究设计与样本

  • 单中心实施经验描述,地点为辛辛那提儿童医院医疗中心(四级护理非营利性儿科学术医疗中心)。

主要发现

  • 2004年该中心实施CYP2D6代谢表型检测以指导可待因处方。
  • 检测使用量在研究项目要求检测时增加,在FDA对可待因的警告导致羟考酮处方增加时下降。
  • 教育和电子健康记录功能提高了处方者对基因型指导术后羟考酮处方的依从性,尽管对羟考酮处方存在感知效用不足。

临床怎么用

  • 对处方者(如疼痛和镰状细胞团队)以及患者和家庭进行以阿片类药物为重点的药物遗传学检测教育。
  • 利用电子健康记录功能支持基因型指导的阿片类药物处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We describe the implementation of CYP2D6-focused pharmacogenetic testing to guide opioid prescribing in a quaternary care, nonprofit pediatric academic medical center. SUMMARY: Children are often prescribed oral opioids after surgeries, for cancer pain, and occasionally for chronic pain. In 2004, Cincinnati Children's Hospital Medical Center implemented pharmacogenetic testing for CYP2D6 metabolism phenotype to inform codeine prescribing. The test and reports were updated to align with changes over time in the testing platform, the interpretation of genotype to phenotype, the electronic health record, and Food and Drug Administration (FDA) guidance. The use of the test increased when a research project required testing and decreased as prescribing of oxycodone increased due to FDA warnings about codeine. Education about the opioid-focused pharmacogenetic test was provided to prescribers (eg, the pain and sickle cell teams) as well as patients and families. Education and electronic health record capability increased provider compliance with genotype-guided postsurgical prescribing of oxycodone, although there was a perceived lack of utility for oxycodone prescribing. CONCLUSION: The implementation of pharmacogenetic testing to inform opioid prescribing for children has evolved with accumulating evidence and guidelines, requiring changes in reporting of results and recommendations.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Ramsey LB, Prows CA, Chidambaran V, et al. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center. Am J Health Syst Pharm. 2023. PMID: 36715063. doi:10.1093/ajhp/zxad025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。